<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656797</url>
  </required_header>
  <id_info>
    <org_study_id>sor017715ctil</org_study_id>
    <nct_id>NCT02656797</nct_id>
  </id_info>
  <brief_title>Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis</brief_title>
  <official_title>Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison between placebo gel treatment to topical liposomal amphotericin B gel treatment
      for cutaneous leishmaniasis of Leishmania species major and tropica.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double blind, placebo controlled study. The study will include 108 patients with
      cutenous leishmaniasis of Leishmania species major and tropica, confired by Polymerase Chain
      Reaction of a sample from a lesion.

      Cure rate will be compared between patients treated with Amphotericin-B 0.4% Liposomal Gel
      and patients treated with placebo gel preparation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete re-epithelization</measure>
    <time_frame>Day 28 from enrollement</time_frame>
    <description>Absence of ulceration, induration, erosion and</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion size</measure>
    <time_frame>Day 28 and day 56 from enrollement</time_frame>
    <description>Defined by the multiplication of lesion length and width</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete re-epithelization</measure>
    <time_frame>Day 28 from enrollement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin manifestations</measure>
    <time_frame>Day 28 and day 56 from enrollement</time_frame>
    <description>Pruritus, pain, etching, discharge, bloating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of lesihmania infection</measure>
    <time_frame>Day 56 from enrollement</time_frame>
    <description>Evaluated by PCR test from a sample acquired from the lesion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>AM-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical Amphotericin-B 0.4% liposomal gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gel preparation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Amphotericin-B 0.4% liposomal gel</intervention_name>
    <description>Topical Amphotericin-B 0.4% liposomal gel</description>
    <arm_group_label>AM-B</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cutenous leishmaniasis confirmed by PCR (Leishmania species major or tropica)

          -  1 to 5 lesions

          -  Signed informed consent

        Exclusion Criteria:

          -  Facial lesions

          -  Significant co-morbidity

          -  Pregnancy or breast-feeding at enrollment

          -  Previous treatment for leishmaniasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Horev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soroka University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir Horev, MD</last_name>
    <phone>+97286400325</phone>
    <email>amirhor@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mor Portnikov</last_name>
    <phone>+97286244245</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Horev</last_name>
      <email>amirhor@clalit.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Soroka University Medical Center</investigator_affiliation>
    <investigator_full_name>AMIR HOREV</investigator_full_name>
    <investigator_title>Head, Pediatric dermatology Service, Soroka University Medical Center</investigator_title>
  </responsible_party>
  <keyword>Leishmania major</keyword>
  <keyword>Leishmania tropica</keyword>
  <keyword>Amphotericin B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

